title: Efficacy of aprepitant in patients with advanced or recurrent lung cancer receiving moderately emetogenic chemotherapy.
abstract: OBJECTIVE
  To evaluate the efficacy of a combination of aprepitant and conventional antiemetic therapy in patients with advanced or recurrent lung cancer receiving moderately emetogenic chemotherapy (MEC).
  
  
  METHODS
  Patients with advanced or recurrent lung cancer who were treated with MEC regimens at the Department of Respiratory Medicine, Fukuoka University Hospital, were included and classified into the following groups: control group (treatment: 5-HT3 receptor antagonists + dexamethasone) and aprepitant group (treatment: 5-HT3 receptor antagonists + dexamethasone + aprepitant). The presence or absence of chemotherapy-induced nausea and vomiting (CINV) was evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE) v4.0; patients with grade 1 or above were considered positive for CINV. Food intake per day, completion of planned chemotherapy, and progression-free survival (PFS) achieved by chemotherapy were investigated.
  
  
  RESULTS
  The complete suppression rate of nausea in the aprepitant group was significantly higher than that in the control group (p = 0.0043). Throughout the study, the food intake in the aprepitant group was greater than that in the control group, with the rate being significantly higher, in particular, on day 5 (p = 0.003). The completion rate of planned chemotherapy was also higher in the aprepitant group (p = 0.042). PFS did not differ significantly, but tended to be improved in the aprepitant group.
  
  
  CONCLUSIONS
  The aprepitant group showed significantly higher complete suppression of nausea, food intake on day 5, and completion of planned chemotherapy than the control group.
authors.affiliation: Department of Respiratory Medicine, Fukuoka University Faculty of Medicine, Fukuoka, Japan. junjiuchino@yahoo.co.jp
authors.forename: Junji
authors.initials: J
authors.lastname: Uchino
authors.forename: Ryosuke
authors.initials: R
authors.lastname: Hirano
authors.forename: Naoki
authors.initials: N
authors.lastname: Tashiro
authors.forename: Yuji
authors.initials: Y
authors.lastname: Yoshida
authors.forename: Shinichiro
authors.initials: S
authors.lastname: Ushijima
authors.forename: Takemasa
authors.initials: T
authors.lastname: Matsumoto
authors.forename: Keiichi
authors.initials: K
authors.lastname: Ohta
authors.forename: Keita
authors.initials: K
authors.lastname: Nakatomi
authors.forename: Koichi
authors.initials: K
authors.lastname: Takayama
authors.forename: Masaki
authors.initials: M
authors.lastname: Fujita
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Nakanishi
authors.forename: Kentaro
authors.initials: K
authors.lastname: Watanabe
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000932:Antiemetics / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D000077608:Aprepitant; D016022:Case-Control Studies; D003907:Dexamethasone / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009025:Morpholines / Q000627:therapeutic use*; D009325:Nausea / Q000139:chemically induced / Q000188:drug therapy*; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D009367:Neoplasm Staging; D011379:Prognosis; D012189:Retrospective Studies; D058831:Serotonin 5-HT3 Receptor Antagonists / Q000627:therapeutic use; D015996:Survival Rate; D014839:Vomiting / Q000139:chemically induced / Q000188:drug therapy*
chemical_list: D000893:Anti-Inflammatory Agents; D000932:Antiemetics; D009025:Morpholines; D058831:Serotonin 5-HT3 Receptor Antagonists; D000077608:Aprepitant; D003907:Dexamethasone